One-Time Gene Therapy for hemophilia B
The Licensing Executives Society (LES) has recognized with its “Deals of Distinction” Award licenses granted by the NIH intramural research program to uniCure N.V. based in Amsterdam along with its global partner CSL Behring. As a result of these licenses on November 22, 2022, the U.S. Food and Drug Administration approved Hemgenix®, the world’s first gene therapy for hemophilia B. It represents an historic achievement based on more than a two decades of research and clinical development through a government /industry partnership and license agreements.